- Stocks
- Healthcare
- NASDAQ: LXRX

Price (delayed)

$4.64

Market cap

$669.96M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.06

Enterprise value

$583.97M

LXRX's debt has dropped by 95% year-on-year

Lexicon Pharmaceuticals's quick ratio has increased by 11% from the previous quarter and by 4.3% YoY

Lexicon Pharmaceuticals's equity has surged by 178% YoY but it has decreased by 2.4% QoQ

The net income has plunged by 115% YoY but it has soared by 78% from the previous quarter

LXRX's revenue has plunged by 95% YoY and by 33% from the previous quarter

The company's gross profit has shrunk by 95% YoY and by 34% QoQ

What are the main financial stats of LXRX

Market
Valuations
Earnings

Shares outstanding

144.39M

Market cap

$669.96M

Enterprise value

$583.97M

Price to earnings (P/E)

N/A

Price to book (P/B)

4.39

Price to sales (P/S)

41.52

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

36.45

Revenue

$16.02M

EBIT

-$3.34M

EBITDA

-$1.28M

Free cash flow

-$135.19M

Per share
Balance sheet
Liquidity

EPS

-$0.06

Free cash flow per share

-$0.94

Book value per share

$1.06

Revenue per share

$0.11

TBVPS

$1.04

Total assets

$193.26M

Total liabilities

$40.71M

Debt

$11.66M

Equity

$152.55M

Working capital

$106.42M

Debt to equity

0.08

Current ratio

3.73

Quick ratio

3.63

Net debt/EBITDA

67.39

Margins
Efficiency
Dividend

EBITDA margin

-8%

Gross margin

91.5%

Net margin

-80.6%

Operating margin

-38.7%

Return on assets

-5.8%

Return on equity

-13.4%

Return on invested capital

-3.7%

Return on capital employed

-2.2%

Return on sales

-20.9%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Lexicon Pharmaceuticals stock price performed over time

Intraday

-2.11%

1 week

-4.72%

1 month

8.16%

1 year

150.81%

YTD

35.67%

QTD

-20.95%

How have Lexicon Pharmaceuticals's revenue and profit performed over time

Revenue

$16.02M

Gross profit

$14.66M

Operating income

-$6.2M

Net income

-$12.92M

Gross margin

91.5%

Net margin

-80.6%

The net income has plunged by 115% YoY but it has soared by 78% from the previous quarter

The operating income has dropped by 106% year-on-year but it has surged by 87% since the previous quarter

LXRX's revenue has plunged by 95% YoY and by 33% from the previous quarter

The company's gross profit has shrunk by 95% YoY and by 34% QoQ

What is Lexicon Pharmaceuticals's growth rate over time

What is Lexicon Pharmaceuticals stock price valuation

P/E

N/A

P/B

4.39

P/S

41.52

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

36.45

The company's EPS has shrunk by 108% YoY but it has surged by 89% QoQ

Lexicon Pharmaceuticals's equity has surged by 178% YoY but it has decreased by 2.4% QoQ

LXRX's price to sales (P/S) is 126% more than its last 4 quarters average of 18.4

LXRX's revenue has plunged by 95% YoY and by 33% from the previous quarter

How efficient is Lexicon Pharmaceuticals business performance

The company's return on sales has shrunk by 167% YoY but it has surged by 89% QoQ

LXRX's ROA has shrunk by 125% YoY but it has soared by 73% QoQ

LXRX's ROIC has plunged by 115% YoY but it has soared by 84% from the previous quarter

The company's return on equity has shrunk by 111% YoY but it has surged by 84% QoQ

What is LXRX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for LXRX.

How did Lexicon Pharmaceuticals financials performed over time

LXRX's total liabilities has dropped by 87% year-on-year and by 14% since the previous quarter

The total assets has declined by 48% year-on-year and by 5% since the previous quarter

LXRX's debt is 92% smaller than its equity

Lexicon Pharmaceuticals's equity has surged by 178% YoY but it has decreased by 2.4% QoQ

Lexicon Pharmaceuticals's debt to equity has shrunk by 98% YoY but it has increased by 14% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.